Delivra Health Brands Inc.
Record Revenue and New Products Boost Market Sentiment
Published: 5/27/2024
Author: FRC Analysts
Sector: Healthcare | Industry: Drug Manufacturers-Specialty & Generic
Ticker Symbols:DHBUF - NASDAQ 🔹DHB.V - TSX 🔹
Rating and Key Data
| Metrics | Value |
|---|---|
| Current Price | CAD $0.04 |
| Fair Value | CAD $0.08 |
| Risk | 3 |
| 52 Week Range | CAD $0.010-0.055 |
| Shares O/S (M) | 313 |
| Market Cap. (M) | CAD $14 |
| Current Yield (%) | N/A |
| P/E (forward) | N/A |
| P/B | 4.0 |
Already a subscriber?
Want to know the fair value of the stock?
Subscribe for free to get exclusive insights and data.
Report Highlights
- DHB is up 29% since our previous report in February 2024, and 80% since our initiating report in September 2023.
- Q3-FY2024 (ended March 2024) revenue was up 31% YoY, in line with our estimate, driven by robust sales growth across all of its brands. DHB sells sleep aid products through its Dream Water brand, and pain relief products through its LivRelief and LivRelief Infused brands. In Q3, 69% of sales came from the U.S., and the Middle East, and 31% from Canada.
- Products are available at over 30k+ distribution points including established retail/pharmacy chains such as Shoppers Drug Mart, Walmart (NYSE: WMT), Kroger (NYSE: KR), Circl
